Study in Nature Aging reveals how design choices and cohort biases alter estimates of age-varying genetic effects

An analysis published in Nature Aging shows that cross-sectional and longitudinal designs can yield divergent estimates of age-varying genetic effects on complex traits, primarily due to cohort confounding and participation bias.

Researchers investigated how cross-sectional (between-subject) and longitudinal (within-subject) designs influence the inference of age-varying genetic effects on complex traits.

The study reported that the estimated age-varying genetic effects from both designs were highly concordant in direction, matching in 84.21% of the 57 identified variants.

However, the designs showed only moderate agreement in effect-size magnitude, yielding a Pearson correlation of r = 0.51.

The researchers found that confounding by gene-by-birth-year (cohort) effects accounted for the largest proportion of variance in these effect-size differences, representing 70.8% of the variance across single-nucleotide polymorphisms (SNPs) with age-varying effects.

Participation bias accounted for an additional 11.6% of the differences, whereas unmodeled nonlinear age trajectories contributed 4.2%.

Determining how genetic influences change over time is key to predicting disease trajectories and designing age-targeted interventions.

Because neither cross-sectional nor longitudinal designs are immune to specific limitations, relying on a single approach can generate skewed parameters for gene-trait associations.

The authors suggest integrating both designs to control for cohort effects and participation bias, resulting in a more accurate model of how genetic effects change over the lifespan.

Longevity discovery platforms that depend on raw, unadjusted biobank data to identify target genes may face elevated development risks if their screening models overlook cohort confounding.

The findings suggest that multi-design integration could become a necessary analytical standard to rigorously validate the effect sizes of genetic targets before advancing them into high-cost drug development programs.

The adoption of integrated longitudinal and cross-sectional modeling frameworks by computational biology firms and population-scale genomic databases to refine their target pipelines.